TXG
10x Genomics Inc Class A · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website 10xgenomics.com
- Employees(FY) 1243
- ISIN US88025U1097
Performance
+2.16%
1W
-23.9%
1M
-36.97%
3M
-24.77%
6M
-50.89%
YTD
-49.11%
1Y
Profile
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Investment Analysis Report: TXG
Overview
In this investment analysis report, we will delve into the financial statements of TXG, a company operating in the Health Technology sector within the Biotechnology industry. We will analyze the company's Balance Sheets, Income Statements, and Cashflow Statements over the past three years to gain insights...
Technical Analysis of TXG 2024-05-03
Overview:
In analyzing the technical indicators for TXG over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions for potential inve...
Recent News & Updates
- 2024-05-02 16:05
- 2024-05-02 06:34
10x Genomics First Quarter 2024 Earnings: In Line With Expectations(Simply Wall St.)
- 2024-05-02 04:05
- 2024-05-01 18:04
- 2024-05-01 12:59
- 2024-05-01 11:33
10x Genomics, Inc. (NASDAQ:TXG) Q1 2024 Earnings Call Transcript(Insider Monkey)
- 2024-05-01 11:05
Q1 2024 10X Genomics Inc Earnings Call(Thomson Reuters StreetEvents)
- 2024-05-01 03:27
- 2024-04-30 18:30
- 2024-04-30 17:43
- 2024-04-30 16:38
10x Genomics: Q1 Earnings Snapshot(Associated Press Finance)
- 2024-04-30 16:05
- 2024-04-30 13:01
- 2024-04-30 08:57
- 2024-04-30 04:05
- 2024-04-29 11:01
- 2024-04-29 07:20
- 2024-04-26 11:30
- 2024-04-25 11:28
11 Oversold MidCap Stocks To Buy Now(Insider Monkey)
- 2024-04-24 23:28
11 Oversold MidCap Stocks To Buy Now(Insidermonkey)
- 2024-04-24 09:35
- 2024-04-23 21:35
- 2024-04-23 10:01
- 2024-04-22 22:01
- 2024-04-22 12:00
- 2024-04-22 00:00
- 2024-04-18 06:46
Bruker to acquire Nanostring for $393M(MedTech Dive)
- 2024-04-10 16:05
- 2024-04-10 04:05
- 2024-03-26 09:00
Page 1 of 6
previousnext